Company Liminal BioSciences Inc. Toronto S.E.
Equities
LMNL
CA53272L1031
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 13/07/08 | |
Director of Finance/CFO | 51 | 01/03/22 | |
Patrick Sartore
PSD | President | 49 | 31/12/05 |
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/19 |
Director/Board Member | 67 | 13/05/14 | |
Shrinal Inamdar
IRC | Investor Relations Contact | - | - |
Marie Iskra
LAW | General Counsel | 48 | 31/08/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/19 |
Director/Board Member | 67 | 13/05/14 | |
Alek Krstajic
CHM | Chairman | 60 | 31/08/20 |
Neil Klompas
BRD | Director/Board Member | 52 | 30/04/19 |
Eugene Siklos
BRD | Director/Board Member | 60 | 31/08/20 |
Director/Board Member | 63 | 30/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,249,534 | 1,258,903 ( 38.74 %) | 0 | 38.74 % |
Company contact information
Liminal BioSciences, Inc.
440, boulevard Armand-Frappier Suite 300
H7V 4B4, Laval
+450 781 0115
http://www.liminalbiosciences.com![address Liminal BioSciences Inc.(LMNL)](https://cdn.zonebourse.com/static/address/61487853.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |